The role of infectious agents in pulmonary and systemic vascular disease.

Abstract:

:With emphasis on the pulmonary circulation, three general types of vascular disease are discussed: fibroproliferative (atherosclerosis), cellular proliferative (endothelial neoplasms) and inflammatory (granulomatous vasculitis). The causes of these phenotypic responses are invariably multifactorial, but infectious agents including viruses, Chlamydia, Helicobacter, Rickettsia, mycobacteria and other infectious agents have been increasingly implicated in the pathophysiology. The classifications of vascular diseases are complicated and confusing and many eponymous diseases are specific variations of more general disease processes. The pivotal role of the monocyte/macrophage and T-cells is discussed, particularly with regard to intracellular infections. In addition to antimicrobial therapy, modifications of macrophage function by IFN-gamma and blockade of TNF are attractive areas for therapeutic research. Diseases with many synergistic causes will probably also require multifaceted therapeutic interventions.

authors

Egermayer P

doi

10.1517/14656566.2.7.1093

keywords:

subject

Has Abstract

pub_date

2001-07-01 00:00:00

pages

1093-7

issue

7

eissn

1465-6566

issn

1744-7666

journal_volume

2

pub_type

杂志文章,评审
  • Pharmacotherapeutic strategies for managing comorbid depression and diabetes.

    abstract::Introduction: The increasing prevalence of comorbid depression and diabetes exerts a heavy burden on global health. Co-occurrence of depression and diabetes is common, affecting 14% to 35.8% of patients with diabetes, leading to a higher mortality and morbidity rate, more micro- and macro-vascular diseases and more co...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1622090

    authors: Li HQ,Chi S,Dong Q,Yu JT

    更新日期:2019-09-01 00:00:00

  • Pemetrexed for the treatment of non-small cell lung cancer.

    abstract:INTRODUCTION:Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed , a multi-target folate antagonist, has improved the survival of non-squamous...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.802774

    authors: Genova C,Rijavec E,Truini A,Coco S,Sini C,Barletta G,Dal Bello MG,Alama A,Savarino G,Pronzato P,Boccardo F,Grossi F

    更新日期:2013-08-01 00:00:00

  • Treatment of bacterial vaginosis: what we have and what we miss.

    abstract:INTRODUCTION:The disturbing, foul-smelling discharge of bacterial vaginosis (BV) is a nuisance to women. Treatment possibilities for BV are limited and only achieve complete cure in 65 to 85% of cases. In most women, the condition relapses within weeks to months after treatment. AREAS COVERED:In search of new therapeu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.881800

    authors: Donders GG,Zodzika J,Rezeberga D

    更新日期:2014-04-01 00:00:00

  • Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.

    abstract:INTRODUCTION:Docetaxel and paclitaxel are among the most active agents for the treatment of breast cancer. These first-generation taxanes are extremely hydrophobic; therefore, solvents are needed for its parenteral administration. Albumin nanoparticle technology allows for the transportation of such hydrophobic drugs w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.651127

    authors: Guarneri V,Dieci MV,Conte P

    更新日期:2012-02-01 00:00:00

  • Ziconotide: a clinical update and pharmacologic review.

    abstract:INTRODUCTION:Ziconotide is an N-type calcium channel antagonist to treat chronic pain that is delivered intrathecally. It is the only intrathecal, FDA-approved, non-opioid analgesic and is recommended as first-line therapy. Despite these advantages, a small therapeutic window limits ziconotide's clinical utility, with ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.784269

    authors: Pope JE,Deer TR

    更新日期:2013-05-01 00:00:00

  • Novel therapy for childhood acute lymphoblastic leukemia.

    abstract:INTRODUCTION:During recent decades, the prognosis of childhood acute lymphoblastic leukemia (ALL) has improved dramatically, nowadays, reaching a cure rate of almost 90%. These results are due to a better management and combination of old therapies, refined risk-group stratification and emergence of minimal residual di...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1340938

    authors: Santiago R,Vairy S,Sinnett D,Krajinovic M,Bittencourt H

    更新日期:2017-08-01 00:00:00

  • Ramipril in the treatment of vascular diseases.

    abstract::Ramipril is an angiotensin-converting enzyme inhibitor that has been extensively studied in randomised, controlled clinical trials in patients with cardiovascular diseases. Therapy with ramipril in patients with various cardiovascular disorders has demonstrated significant and clinically important reductions in cardio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.11.1911

    authors: Rokoss MJ,Teo KK

    更新日期:2005-09-01 00:00:00

  • The RTOG Outcomes Model: economic end points and measures.

    abstract::Recognising the value added by economic evaluations of clinical trials and the interaction of clinical, humanistic and economic end points, the Radiation Therapy Oncology Group (RTOG) has developed an Outcomes Model that guides the comprehensive assessment of this triad of end points. This paper will focus on the econ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.3.513

    authors: Konski A,Watkins-Bruner D,RTOG (Radiation Therapy Oncology Group) Outcomes Model.

    更新日期:2004-03-01 00:00:00

  • 1st International Conference on Panic Attacks: diversity of theories and treatments. september 5-8, 2003, London.

    abstract::The 1st International Conference on Psychophysiology of Panic Attacks focused on the diversity of treatments and theories in this complex condition. Experimental research topics were featured, as well as treatment strategies, case studies and patient perspectives. The conference aimed to create a strong multi-cultural...

    journal_title:Expert opinion on pharmacotherapy

    pub_type:

    doi:10.1517/14656566.5.4.977

    authors: Perry D

    更新日期:2004-04-01 00:00:00

  • Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections.

    abstract:OBJECTIVE:Beta-lactamase producing bacteria present a major problem in treating lower respiratory tract infections. The objective of this study was to evaluate efficacy and safety of cefotaxime-sulbactam combination versus amoxicillin-clavulanic acid injection as an alternative therapeutic option for treatment of lower...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/14656566.9.16.2751

    authors: Pareek A,Kulkarni M,Daga S,Deshpande A,Chandurkar N

    更新日期:2008-11-01 00:00:00

  • Evaluation of injection force of three insulin delivery pens.

    abstract:OBJECTIVE:Reduced injection force is among the modifications to the Next Generation FlexPen (NGFP). This force was compared with two other prefilled pens: SoloStar (SS) and KwikPen (KP). RESEARCH DESIGN/METHODS:The injection force of the pens was measured, with either a BD Micro-Fine 31G thin-wall needle, or a NovoFin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560903018929

    authors: Asakura T,Seino H,Kageyama M,Yohkoh N

    更新日期:2009-06-01 00:00:00

  • Emerging paradigms in targeted treatments for Asian patients with NSCLC.

    abstract:INTRODUCTION:EGFR-targeted drugs have been successfully approved in many countries and have demonstrated higher efficacy and lower toxicity than chemotherapy in molecularly defined subgroups of patients. Significant advances in clinical trials and studies focusing on targeted therapies have rapidly developed in Asia. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1040391

    authors: Ke EE,Zhou Q,Wu YL

    更新日期:2015-06-01 00:00:00

  • Challenges and treatment options for rheumatoid arthritis during pregnancy.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) can spontaneously improve during pregnancy. However, a considerable proportion of patients can experience a flare and high disease activity has been associated with an increased risk of adverse pregnancy outcome. Thus, the treatment of RA in pregnant women should be selected takin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1197204

    authors: Gerosa M,Schioppo T,Meroni PL

    更新日期:2016-08-01 00:00:00

  • MP29-02: a breakthrough for the treatment of allergic rhinitis.

    abstract:INTRODUCTION:Allergic rhinitis (AR) can be challenging to treat. For many patients, current therapies (including multiple therapies) provide insufficient symptom relief. There is, therefore, a clear unmet medical need for a new and more effective AR treatment option. MP29-02 ( Dymista ) is a novel intranasal formulatio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.828693

    authors: Bernstein JA

    更新日期:2013-10-01 00:00:00

  • Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.

    abstract:INTRODUCTION:PI3K inhibition with idelalisib (at that time CAL-101) was at the forefront of the development of molecularly targeted therapies in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) and follicular lymphoma. However, after initial approval, subsequent trials identified specific immune-medi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1737010

    authors: Kienle DL,Stilgenbauer S

    更新日期:2020-06-01 00:00:00

  • Paroxetine mesylate: comparable to paroxetine hydrochloride?

    abstract:IMPORTANCE OF THE FIELD:Currently available small case reports clearly propose that existing regulatory procedures to approve generic versions only require essential bioequivalence, have limitations and fail to meet stricter scientific and clinical demands. AREAS COVERED IN THIS REVIEW:Data indicate that paroxetine me...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903451708

    authors: Pae CU,Misra A,Ham BJ,Han C,Patkar AA,Masand PS

    更新日期:2010-02-01 00:00:00

  • Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.

    abstract::Clopidogrel has become a mainstay in the management of acute coronary syndrome patients over the past decade, as well as an essential component of percutaneous coronary intervention (PCI) pharmacotherapy. Until recently, no prospective study has evaluated the effectiveness of clopidogrel in the setting of an ST-segmen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.12.1669

    authors: Hamdalla H,Moliterno DJ

    更新日期:2006-08-01 00:00:00

  • Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time?

    abstract::Glycosuria is being increasingly recognised as not only a symptom but also as a novel therapeutic approach in the management of type 2 diabetes mellitus (T2DM). This is accomplished through sodium glucose co-transporter 2 (SGLT2) inhibitors. Consequently, the safety and efficacy of these new agents have been thoroughl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2015.994505

    authors: Pafili K,Papanas N

    更新日期:2015-03-01 00:00:00

  • A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial.

    abstract:BACKGROUND:This comparison of PRAsugrel and clopidogrel in Japanese patients with ischemic STROke (PRASTRO)-I trial investigates the noninferiority of prasugrel to clopidogrel sulfate in the prevention of recurrence of primary events (ischemic stroke, myocardial infarction, and death from other vascular causes), and th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/14656566.2018.1444029

    authors: Nagao T,Toyoda K,Kitagawa K,Kitazono T,Yamagami H,Uchiyama S,Tanahashi N,Matsumoto M,Minematsu K,Nagata I,Nishikawa M,Nanto S,Abe K,Ikeda Y,Ogawa A

    更新日期:2018-04-01 00:00:00

  • Brimonidine tartrate for the treatment of glaucoma.

    abstract:INTRODUCTION:Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. Its use has been popularized due to its effects on aqueous suppression and uveoscleral outflow, as well as the suggestion of neuroprotection. Although available with alternative preservative vehicles,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1544241

    authors: Oh DJ,Chen JL,Vajaranant TS,Dikopf MS

    更新日期:2019-01-01 00:00:00

  • Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.

    abstract::Sertraline (Zoloft, Pfizer Inc.) is a selective serotonin re-uptake inhibitor (SSRI) which has been approved by the US FDA for the treatment of premenstrual dysphoric disorder (PMDD). PMDD is a severe form of premenstrual syndrome (PMS) which affects at least 5 - 8% of women of reproductive age. It is characterised by...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.11.2065

    authors: Halbreich U,Kahn LS

    更新日期:2003-11-01 00:00:00

  • Itraconazole.

    abstract::Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.2.287

    authors: Piérard GE,Arrese JE,Piérard-Franchimont C

    更新日期:2000-01-01 00:00:00

  • Which antihypertensive drugs are the most nephroprotective and why?

    abstract:IMPORTANCE OF THE FIELD:Hypertension is a major independent risk factor for kidney disease and for faster renal function loss. Choice of antihypertensive strategies with highest nephroprotective effect is crucial to prevent or reverse progression to end stage renal disease (ESRD). AREAS COVERED IN THIS REVIEW:The pres...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.521742

    authors: Cravedi P,Ruggenenti P,Remuzzi G

    更新日期:2010-11-01 00:00:00

  • Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review.

    abstract::Introduction: The current recommendations of chronic obstructive pulmonary disease (COPD) suggest to escalate from inhaled corticosteroid/long-acting β2-adrenoceptor agonist (ICS/LABA) treatment to triple therapy in patients experiencing persistent breathlessness, exercise limitation, or exacerbation. The addition of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1845314

    authors: Ritondo BL,Puxeddu E,Calzetta L,Cazzola M,Rogliani P

    更新日期:2020-11-11 00:00:00

  • Treatment of adult short bowel syndrome patients with teduglutide.

    abstract:INTRODUCTION:Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.644787

    authors: Nørholk LM,Holst JJ,Jeppesen PB

    更新日期:2012-02-01 00:00:00

  • Synthetic pharmacotherapy for lupus nephritis.

    abstract:INTRODUCTION:Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aime...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1276563

    authors: Moroni G,Ponticelli C

    更新日期:2017-02-01 00:00:00

  • A pharmacogeneticist's look at drug effects and the drug development process: an overview.

    abstract::This paper describes the functional roles of the closely related pharmacogenetic and pharmacogenomic sciences in medicine. Firstly, they provide means for a better understanding of the function of drugs, and particularly of the differences of drug action between individuals and also between racially categorised popula...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.8.1299

    authors: Kalow W

    更新日期:2005-07-01 00:00:00

  • The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.

    abstract::A randomized Phase III trial tested the efficacy of pemetrexed as maintenance treatment in patients with advanced non-small-cell lung cancer (NSCLC) who were without progression after completing four cycles of first-line platinum-based chemotherapy. The primary endpoint of the trial was progression-free survival (PFS)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14656560903485672

    authors: Gridelli C,Di Maio M

    更新日期:2010-02-01 00:00:00

  • Safe Therapeutic Economic Pharmaceutical Selection (STEPS): development, introduction and use in Northern Ireland.

    abstract::A number of medicine selection methods have been used worldwide for formulary purposes. In Northern Ireland, integrated medicines management is being developed, and related projects have been carried out. This paper deals with the description of the STEPS (Safe Therapeutic Economic Pharmaceutical Selection) programme....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.8.s1.s57

    authors: Scott M,Timoney M,Mairs J,Crealey G,Al Abaddi I,Brenninkmeijer R,Janknegt R,McElnay J

    更新日期:2007-10-01 00:00:00

  • Empagliflozin for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Despite the availability of numerous anti-diabetes drugs and treatment guidelines, many patients with type 2 diabetes mellitus (T2DM) do not reach recommended targets for glycemic control. There remains an unmet need for effective and well-tolerated anti-diabetes agents that can be used as monotherapy or i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.966078

    authors: Jahagirdar V,Barnett AH

    更新日期:2014-11-01 00:00:00